Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 34
- Registration Number
- NCT01497093
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 42
- Registration Number
- NCT01490437
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
- Conditions
- Chemotherapy-induced Nausea and VomitingEffects of ChemotherapySarcomaAdverse Effects of Medical Drugs
- Interventions
- Drug: FosaprepitantDrug: DexamethasoneDrug: 5HT3 receptor antagonistDrug: Ifosfamide-based chemotherapy (AI)Drug: DoxorubicinDrug: MesnaDrug: IfosfamideDrug: Vincristine
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT01490060
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Emory University
- Target Recruit Count
- 8
- Registration Number
- NCT01485835
- Locations
- 🇺🇸
The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
- Conditions
- Acute Lymphoblastic LeukemiaPrecursor B-Cell Lymphoblastic LeukemiaPrecursor T-Cell Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Target Recruit Count
- 23
- Registration Number
- NCT01483690
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇦🇺Children's Hospital at Westmead, Westmead, New South Wales, Australia
🇦🇺Sydney Children's Hospital, Sydney, Australia
ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT01481194
- Locations
- 🇩🇰
Department of Hematology, Vejle, Denmark
Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Drug: DexamethasoneDrug: Placebo
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Emory University
- Target Recruit Count
- 165
- Registration Number
- NCT01477762
- Locations
- 🇺🇸
Grady Health System, Atlanta, Georgia, United States
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 92
- Registration Number
- NCT01478581
- Locations
- 🇺🇸
SITE-5, Baltimore, Maryland, United States
🇺🇸SITE-4, Boston, Massachusetts, United States
🇺🇸SITE-13, La Jolla, California, United States
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 185
- Registration Number
- NCT01478048
- Locations
- 🇺🇸
Cancer Center Of Acadiana, Lafayette, Louisiana, United States
🇺🇸Medical University Of South Carolina, Charleston, South Carolina, United States
🇺🇸Ucla Department Of Medicine, Los Angeles, California, United States
Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting
- Conditions
- Postoperative Nausea and Vomiting (PONV)Nausea
- Interventions
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Sergio Bergese
- Target Recruit Count
- 122
- Registration Number
- NCT01474915
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.